CAR-T Cell Immunotherapy for HCC Targeting GPC3

CAR-T Cell Immunotherapy Clinical Trial

Official title: Chimeric Antigen Receptor-Modified T Cell (CAR-T) Immunotherapy for Hepatocellular Carcinoma (HCC) Targeting Glypican-3 (GPC3)

Status Withdrawn

Clinical Trial Summary

The purpose of this study is to preliminarily evaluate the safety and efficacy of CAR-T cell immunotherapy for GPC3 positive hepatocellular carcinoma.

Clinical Trial Description

Chimeric antigen receptor (CAR) is a recombinant receptor with both antigen-binding and T cell activating functions. Chimeric antigen receptor T cell Immunotherapy has more advantages compared with conventional immunotherapy, especially in dealing with patients of hematologic malignancies and solid malignant tumors.This study design a novel specific Chimeric antigen receptor targeting glypican-3(GPC3) antigen.After CAR-T cell infusion,At periodic intervals, the investigators will evaluate clinical symptoms Improved conditions of this disease.Through this study,the investigators will evaluate the safety and efficacy of CAR-T cell immunotherapy in treating with GPC3 positive malignant glioma patients. ;

Related Conditions & MeSH terms

• CAR-T Cell Immunotherapy
• Carcinoma
• Carcinoma, Hepatocellular
• GPC3 Positive Hepatocellular Carcinoma

• NCT number: NCT02723942
• Study type: Interventional
• Source: Fuda Cancer Hospital, Guangzhou
• Status: Withdrawn
• Phase: Phase 1/Phase 2
• Start date: June 2015
• Completion date: August 15, 2016